K-CAB, Enteresto, Olumiant, Rinvoq signs PVA agreements
By Lee, Tak-Sun | translator Alice Kang
24.12.30 05:06:38
가나다라
0
K-CAB’s refund rate was adjusted…Price of Entresto and Oluminat were cut
Price ceiling for Tremfya and Alprolix was adjusted through PVA
▲HK.InnoN
The domestic P-CAB-based gastroesophageal reflux disease treatment 'K-CAB Tab (tegoprazan, HK Inno.N) and heart failure treatment 'Entresto Film Coated Tab (sacubitril-valsartan-sodium salt complex) the oral JAK inhibitors Olumiant Tab (baricitinib, Lilly), and Rinvoq ER Tab (Upadacitinib hemihydrate, AbbVie) have agreed on a price-volume agreement (PVA) upon negotiations with the National Health Insurance Service.As a result, the refund rate for K-CAB was adjusted, while the price of Entresto and Olumiant will be reduced next month.
According to industry sources on the 27th, 3 products recently agreed to a ‘PVA B type’ negotiations with the NHIS to adjust reimbursement and the price
Lee, Tak-Sun(hooggasi2@dailypharm.com)
If you want to see the full article, please JOIN US (click)